Shares of Pfizer Inc. (NYSE:PFE) reached a new 52-week high on Thursday . The stock traded as high as $36.83 and last traded at $36.70, with a volume of 12,815,228 shares trading hands. The stock had previously closed at $36.31.

Several research firms recently weighed in on PFE. Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $37.97 price objective for the company. in a report on Thursday. Jefferies Group set a $41.50 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Thursday. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $54.00 target price on shares of Pfizer in a report on Monday, June 27th. Deutsche Bank AG reiterated a “buy” rating on shares of Pfizer in a report on Wednesday, June 15th. Finally, TheStreet upgraded shares of Pfizer from a “hold” rating to a “strong-buy” rating in a report on Friday, June 3rd. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. Pfizer presently has a consensus rating of “Buy” and a consensus price target of $38.11.

The firm has a market capitalization of $223.00 billion and a price-to-earnings ratio of 30.14. The firm has a 50-day moving average of $35.15 and a 200 day moving average of $32.24.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.12. The business had revenue of $13 billion for the quarter, compared to analyst estimates of $12 billion. During the same period last year, the business posted $0.51 EPS. Pfizer’s revenue was up 19.3% on a year-over-year basis. On average, analysts anticipate that Pfizer Inc. will post $2.44 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 1st. Stockholders of record on Friday, August 5th will be given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 3.26%. The ex-dividend date of this dividend is Wednesday, August 3rd.

In other news, EVP Laurie J. Olson sold 4,700 shares of the firm’s stock in a transaction dated Wednesday, May 11th. The stock was sold at an average price of $33.50, for a total transaction of $157,450.00. Following the sale, the executive vice president now owns 71,659 shares of the company’s stock, valued at approximately $2,400,576.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Douglas M. Lankler sold 29,700 shares of the firm’s stock in a transaction dated Wednesday, May 4th. The stock was sold at an average price of $33.69, for a total value of $1,000,593.00. Following the sale, the executive vice president now directly owns 124,920 shares in the company, valued at approximately $4,208,554.80. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently added to or reduced their stakes in the company. San Francisco Sentry Investment Group CA raised its position in Pfizer by 0.4% in the fourth quarter. San Francisco Sentry Investment Group CA now owns 32,934 shares of the biopharmaceutical company’s stock valued at $1,063,000 after buying an additional 125 shares during the period. Sheets Smith Wealth Management raised its position in Pfizer by 1.3% in the fourth quarter. Sheets Smith Wealth Management now owns 33,001 shares of the biopharmaceutical company’s stock valued at $1,065,000 after buying an additional 436 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in Pfizer by 4.8% in the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 33,248 shares of the biopharmaceutical company’s stock valued at $1,073,000 after buying an additional 1,524 shares during the period. Mycio Wealth Partners LLC raised its position in Pfizer by 5.8% in the fourth quarter. Mycio Wealth Partners LLC now owns 33,436 shares of the biopharmaceutical company’s stock valued at $1,079,000 after buying an additional 1,825 shares during the period. Finally, Cobblestone Capital Advisors LLC NY raised its position in Pfizer by 12.1% in the fourth quarter. Cobblestone Capital Advisors LLC NY now owns 34,231 shares of the biopharmaceutical company’s stock valued at $1,105,000 after buying an additional 3,700 shares during the period.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.